Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance

EP0057-201

EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy. When EP0057 is combined with Olaparib, it is envisaged that the combination should improve therapeutic responses in the recurrent ovarian cancer disease setting. EP0057 is an investigational nanoparticle-drug conjugate administered intravenously. The rationale for developing EP0057 is to enable selective entry of EP0057 into tumour tissue and as a result create preferential accumulation of EP0057, and therefore of the payload Camptothecin, to translate into maximum tumour cell killing.

2020-12-14

2023-02-17

2023-05-05

Completed

Early phase I

34

Inclusion Criteria: 1. Patients aged ≥ 18 years of age at the time of Informed Consent 2. Ability to understand and provide written informed consent prior to undergoing any study procedures 3. Life expectancy of \> 3 months, as estimated by the investigator 4. Histologically confirmed diagnosis (cytology alone excluded) with high-grade serous ovarian cancer or high-grade endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer 5. BRCA mutational status is known (germline and somatic). (For Patients in Phase 2A, status does not need to be known prior to enrolment) 6. HRD status is known. (For Patients in Phase 2A, status does not need to be known prior to enrolment) 7. At least 1 measurable lesion to assess response by RECIST v1.1 criteria 8. Archival tumour sample must be available. In the absence of an archival tumour biopsy, a tumour tissue biopsy will need to be collected prior to enrolment 9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening 10. Normal organ and bone marrow function: Haemoglobin ≥ 9.0 g/dL Absolute neutrophil count (ANC) ≥ 1.5 x 109 Lymphocyte count ≥ 0.5 x 109 Platelet count ≥ 100 x 109 Total bilirubin ≤ 1.5 institutional upper limit normal (ULN) Serum albumin ≥ 2.5 g/dL AST and ALT ≤ 2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance \> 50 mL/min (calculated using the Cockroft-Gault formula) for patients with creatinine levels above institutional normal Patients not receiving anti-coagulant medication must have an INR of ≤ 1.5 and an aPTT ≤ 1.5 x ULN 11. In the opinion of the Investigator, all other relevant medical conditions must be well-managed and stable for at least 28 days prior to first administration of study drug 12. Willing and able to participate in all required evaluations and procedures in this study protocol 13. Contraception: Each female subject of childbearing potential must agree to use a highly effective method of contraception (i.e., a method with less than 1% failure rate per year \[e.g., sterilization, hormone implants, hormone injections, some intrauterine devices, vasectomized partner, or combined birth control pills\]) from screening until 6 months after the last dose of EP0057 or Olaparib, whichever was taken last. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative serum or urine pregnancy test within 24 hours prior to EP0057 dosing on Day 1 of each Cycle (and must not be lactating). Each female subject will be considered to be of childbearing potential unless she has been surgically sterilised by hysterectomy or bilateral tubal ligation/salpingectomy or has been postmenopausal for at least 1 year. Cohort 1 patients (Phase 2A and 2B) must be/have: 14. Received no more than 1 prior line of therapy which must be platinum-based chemotherapy 15. Primary Platinum Resistant after completion of first line platinum-based chemotherapy Cohort 2 patients (Phase 2A and 2B) must have: 16. Received at least 1 prior line of treatment, 1 of which must be platinum-based chemotherapy 17. Received a PARP inhibitor in the maintenance setting as their most recent treatment following a confirmed response by RECIST1.1 (CR or PR) to the last regimen which must be a platinum-based chemotherapy, with maintenance of response by PARP inhibitor lasting ≥ 6 months, with subsequent confirmed disease progression as defined by RECIST v1.1 criteria Exclusion Criteria: 1. Non-epithelial tumour of the ovary, the fallopian tube or the peritoneum 2. Ovarian tumours of low malignant potential or low grade 3. Prior treatment with a topoisomerase I inhibitor 4. Potent inhibitors or inducers of CYP3A4 5. Concurrent treatment with Coumadin (Warfarin) 6. History of stroke, transient ischemic attack, or myocardial infarction, within 6 months prior to C1D1 7. Brain and/or leptomeningeal metastases that are symptomatic or untreated or that require current therapy. Brain imaging must not be older than 12 weeks (at the start of screening). Results with abnormal/unexpected findings of brain MRI should be discussed with the Medical Monitor as part of the screening process 8. Systemic anti-cancer therapy for the disease under study within 3 weeks or 5 half-lives, whichever is longer, of the first dose of study drug 9. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 2 toxicities, which in the opinion of the Investigator should not exclude the patient 10. Patients considered by the Investigator to be at a higher baseline risk for new onset cystitis 11. Patients with a history, or features suggestive, of bone marrow dysplasia or myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) 12. Confirmed QTcF \> 470 msec on screening ECG or congenital long QT syndrome 13. Receiving an investigational anti-cancer treatment concurrently or within 3 weeks or 5 half-lives of either the parent drug or any active metabolite, whichever is longer, prior to the first dose of study drug 14. Any evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol 15. Hypersensitivity to EP0057 or any of its excipients 16. Known history of Human Immunodeficiency Virus infection (HIV) (testing is not required), active infection with SARS-CoV-2, hepatitis B virus (HBV) or hepatitis C virus (HCV) per institutional protocol. Testing for HBV or HCV status is not necessary unless clinically indicated or the patient has a history of HBV or HCV infection. All patients should be tested for an active SARS-CoV-2 infection with an approved diagnostic test kit 17. Malignant disease other than that being treated in this study, with the following exceptions: Malignancies that were treated curatively and have not recurred within 2 years prior to study treatment Completely resected basal cell and squamous cell skin cancers Any malignancy considered to be indolent and that has never required therapy Completely resected carcinoma in situ of any type 18. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results 19. Any major surgical procedure (in the investigator's judgement) within 2 weeks of the first dose of study drug 20. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation) 21. Palliative radiotherapy (e.g., for pain or bleeding) within 6 weeks prior to randomisation or patients who have not completely recovered previous radiotherapy (Grade ≥ 2) from the effects of previous radiotherapy 22. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) Note: Patients with indwelling catheters (e.g.,PleurX) are allowed 23. Hypersensitivity or intolerance (due to safety or other reasons) to PARP inhibitors Cohort 1 patients (Phase 2A and 2B) who: 24. Have primary platinum refractory disease defined as progression during first line treatment with 4-6 cycles of platinum based chemotherapy Cohort 2 patients (Phase 2A and 2B) who: 25. Progress within 6 months during PARP inhibitor maintenance treatment 26. Progress after completion of PARP inhibitor maintenance treatment

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 34, 'type': 'ACTUAL'}}

2023-08-02